NCT07820969

Brief Summary

The purpose of this study is to directly compare the efficacy of suzetrigine vs. oxycodone+acetaminophen vs. alternating acetaminophen/ibuprofen in controlling post-operative pain after the following nail unit procedures.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for phase_4

Timeline
24mo left

Started Oct 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 9, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 15, 2026

Completed
16 days until next milestone

Study Start

First participant enrolled

October 1, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2028

Last Updated

October 1, 2026

Status Verified

September 1, 2026

Enrollment Period

2 years

First QC Date

September 9, 2026

Last Update Submit

September 29, 2026

Conditions

Nail Diseases

Outcome Measures

Primary Outcomes (1)

  • Change in Post-Operative Pain Intensity

    Pot-operative pain intensity measured using the Numeric Rating Scale (NRS, 0-10), where 0 indicates no pain and 10 indicates worst possible pain; higher scores indicate greater pain following nail unit procedures.

    24 hours post nail procedure, 48 hours post nail procedure, 72 hours post nail procedure

Study Arms (3)

Suzetrigine Group

EXPERIMENTAL

Participants in this arm will receive suzetrigine for 5 days for post-operative pain management following nail unit procedures.

Drug: Suzetrigine

Oxycodone + Acetaminophen Combination Group

ACTIVE COMPARATOR

Participants in this arm will receive a combination of oxycodone and acetaminophen for 5 days for post-operative pain management following nail unit procedures.

Drug: Oxycodone/Acetaminophen

Alternating Acetaminophen/Ibuprofen Group

ACTIVE COMPARATOR

Participants in this arm will receive alternating acetaminophen and ibuprofen administered orally every 6 hours for 5 days starting the day of the nail procedure.

Drug: AcetaminophenDrug: Ibuprofen

Interventions

SuzetrigineDRUG

Participants will receive two 50 mg oral tablets on day 1, followed by 50 mg oral tablets every 12 hours for 5 days

Suzetrigine Group
Oxycodone/AcetaminophenDRUG

Participants will receive oral oxycodone 5 mg/acetaminophen 325 mg (Percocet®) as a fixed-dose combination tablet every 6 hours for 5 days, beginning on the day of the nail procedure.

Also known as: Percocet®
Oxycodone + Acetaminophen Combination Group
AcetaminophenDRUG

Participants will receive acetaminophen 650 mg orally every 6 hours, alternating with ibuprofen, for 5 days beginning on the day of the nail procedure.

Alternating Acetaminophen/Ibuprofen Group
IbuprofenDRUG

Participants will receive ibuprofen 400 mg orally every 6 hours, alternating with acetaminophen, for 5 days beginning on the day of the nail procedure.

Alternating Acetaminophen/Ibuprofen Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients age 18+ able to understand and provide written consent in English or Spanish who present to Dr. Brian Morrison's clinic at the University of Miami and are undergoing a nail unit procedure.

You may not qualify if:

  • Patients under the age of 18 or adults unable to consent.
  • Patients who are pregnant or incarcerated.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami, Phillip Frost Dermatology Clinic

Miami, Florida, 33136, United States

Location

MeSH Terms

Conditions

Nail Diseases

Interventions

oxycodone-acetaminophenAcetaminophenIbuprofen

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPhenylpropionatesAcids, CarbocyclicCarboxylic Acids

Study Officials

  • Brian Morrison, MD

    University of Miami

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Brian W Morrison, MD

CONTACT

305-243-4472bmorrison@med.miami.edu

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Clinical

Study Record Dates

First Submitted

September 9, 2026

First Posted

September 15, 2026

Study Start

October 1, 2026

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2028

Last Updated

October 1, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations

US(1)